315 related articles for article (PubMed ID: 21451123)
21. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
[TBL] [Abstract][Full Text] [Related]
23. Downregulating Notch counteracts Kras
Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
[TBL] [Abstract][Full Text] [Related]
24. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
[TBL] [Abstract][Full Text] [Related]
25. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
26. The protein kinase MAP3K19 phosphorylates MAP2Ks and thereby activates ERK and JNK kinases and increases viability of KRAS-mutant lung cancer cells.
Hoang VT; Nyswaner K; Torres-Ayuso P; Brognard J
J Biol Chem; 2020 Jun; 295(25):8470-8479. PubMed ID: 32358059
[TBL] [Abstract][Full Text] [Related]
27. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
28. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
Torti VR; Wojciechowicz D; Hu W; John-Baptiste A; Evering W; Troche G; Marroquin LD; Smeal T; Yamazaki S; Palmer CL; Burns-Naas LA; Bagrodia S
Mol Cancer Ther; 2012 Oct; 11(10):2274-83. PubMed ID: 22752429
[TBL] [Abstract][Full Text] [Related]
29. A Combination of rhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2) and MEK (MAP Kinase/ERK Kinase) Inhibitor PD0325901 Increases Bone Formation in a Murine Model of Neurofibromatosis Type I Pseudarthrosis.
El-Hoss J; Cheng T; Carpenter EC; Sullivan K; Deo N; Mikulec K; Little DG; Schindeler A
J Bone Joint Surg Am; 2014 Jul; 96(14):e117. PubMed ID: 25031379
[TBL] [Abstract][Full Text] [Related]
30. Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.
Shieh A; Ward AF; Donlan KL; Harding-Theobald ER; Xu J; Mullighan CG; Zhang C; Chen SC; Su X; Downing JR; Bollag GE; Shannon KM
Blood; 2013 Jun; 121(24):4884-93. PubMed ID: 23637129
[TBL] [Abstract][Full Text] [Related]
31. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Liu D; Xing M
Thyroid; 2008 Aug; 18(8):853-64. PubMed ID: 18651802
[TBL] [Abstract][Full Text] [Related]
32. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
33. Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors.
Stewart A; Thavasu P; de Bono JS; Banerji U
Ann Oncol; 2015 Jul; 26(7):1504-10. PubMed ID: 25908604
[TBL] [Abstract][Full Text] [Related]
34. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
[TBL] [Abstract][Full Text] [Related]
35. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
[TBL] [Abstract][Full Text] [Related]
36. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
[TBL] [Abstract][Full Text] [Related]
37. MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.
Henderson YC; Chen Y; Frederick MJ; Lai SY; Clayman GL
Mol Cancer Ther; 2010 Jul; 9(7):1968-76. PubMed ID: 20587665
[TBL] [Abstract][Full Text] [Related]
38. PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
Diaz-Flores E; Goldschmidt H; Depeille P; Ng V; Akutagawa J; Krisman K; Crone M; Burgess MR; Williams O; Houseman B; Shokat K; Sampath D; Bollag G; Roose JP; Braun BS; Shannon K
Sci Signal; 2013 Dec; 6(304):ra105. PubMed ID: 24300897
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Andersen NJ; Nickoloff BJ; Dykema KJ; Boguslawski EA; Krivochenitser RI; Froman RE; Dawes MJ; Baker LH; Thomas DG; Kamstock DA; Kitchell BE; Furge KA; Duesbery NS
Mol Cancer Ther; 2013 Sep; 12(9):1701-14. PubMed ID: 23804705
[TBL] [Abstract][Full Text] [Related]
40. Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib).
El-Hoss J; Kolind M; Jackson MT; Deo N; Mikulec K; McDonald MM; Little CB; Little DG; Schindeler A
Bone; 2014 Feb; 59():151-61. PubMed ID: 24269278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
